Image-Guided Cryoablation for Palliation of Painful Bone Metastases: A Systematic Review and Meta-Analysis Publisher



Torabi S^{1, 2} ; Ahmadzade M³ ; Ghorani H^{1, 2} ; Sarvari M^{1, 5} ; Rouientan H⁴ ; Trinh K⁶ ; Manzari Tavakoli G^{1, 5} ; Afsharzadeh M^{1, 7} ; Uppot RN⁸ ; Ghasemirad M³ Show Affiliations
Source: Skeletal Radiology Published:2025

Abstract

Objective: To assess the efficacy of cryoablation in controlling pain from metastatic bone lesions. Materials and methods: A systematic search of PubMed, Embase, Scopus, Cochrane library, and Web of Science was conducted from inception to April 2024, focusing on cryoablation for palliation of painful bone metastases. The inclusion criteria were as follows: studies involving patients over 18 years of age who were affected by bone metastases; bone metastases treated with stand-alone cryoablation; studies reporting patients' pain levels before and at least at one time point after cryoablation; and studies published in English. Results: A total of 844 articles were initially screened, resulting in 12 articles involving 309 patients included. Pain assessments were conducted at various time points ranging from 1 day to 6 months after the cryoablation procedure. Included studies reported significant improvements in pain scores based on the visual analog scale (VAS), the numeric rating scale (NRS) and brief pain inventory—short form (BPI-SF) following treatment at 1, 4, 8 and 12 weeks. The most notable mean difference between pre- and post-procedure pain scores was observed at 12 weeks, with a standardized mean difference of -3.71 (95% confidence interval [CI]: -5.29 to -2.00; p < 0.001). Regarding pain relief outcomes, by the fourth week, the proportion of patients experiencing pain relief was 0.69 (95% CI: 0.62 to 0.75; p < 0.001). Conclusions: Cryoablation could be an effective method for palliation of painful bone metastases. Further studies are needed to compare its efficacy with other palliative methods and to define its role in cancer management. © The Author(s), under exclusive licence to International Skeletal Society (ISS) 2025.